$0.4150
0.062917.86%
Últ. Act.: Oct 28, 3:47 PM
Reviva Pharmaceuticals said the FDA recommended a second Phase 3 trial for its schizophrenia drug brilaroxazine after a pre-NDA meeting.
Puedes comprar acciones de REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc. (OTCQB:RVPH) a través de cualquier corretaje en línea.
No hay competidores como tal para REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc..
REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc. tiene un precio objetivo de consenso de $135.10.
El precio de las acciones de REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) es de 0.415 dólares, actualizado por última vez el 28 de octubre de 2026 a las 15:47 GMT-4.
No hay dividendos previstos para REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc..
No hay informes de resultados previstos para REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc..
No hay ninguna división de acciones prevista para REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc..
REVIVA PHARMA HLDGS INC by Reviva Pharmaceuticals Holdings, Inc. está en el sector Health Care y en la industria Pharmaceuticals. Cotiza en el OTCQB.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and...
